Search Result

Results for "

S. pneumonia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (19) Apoptosis (1) Bacterial (21) Cytochrome P450 (3) DNA/RNA Synthesis (2) Fungal (1) Isotope-Labeled Compounds (4) NF-κB (1) Parasite (4) SARS-CoV (2) Toll-like Receptor (TLR) (1) Topoisomerase (4)
By Research Areas:	Cancer (2) Infection (25) Inflammation/Immunology (6) Metabolic Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2454

CSP1	Bacterial	Infection
CSP1 is a potent and selective ComD1 receptor agonist, with an IC₅₀ of 10.3 nM. CSP1 is a major variants of competence-stimulating peptide (CSP), and it can regulate genetic transformation of S. pneumonia by modulating quorum sensing (QS). CSP1 can act as an antibacterial agent .

HY-100442

Paquinimod 10+ Cited Publications ABR-215757; ABR 25757
Paquinimod (ABR 215757) is a specific and orally active inhibitor of *S100A8/S100A9. Paquinimod rescues the pneumonia* with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-107222

Lysionotin	Others	Inflammation/Immunology
Lysionotin is a flavonoid isolated from Gesneriaceae family. Lysionotin efficiently inhibit α-Toxin (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo. Lysionotin has the potential for the treatment of S. aureus induced pneumonia .

HY-P3078

Amphomycin	Bacterial Antibiotic	Infection
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .

HY-16566

Kanamycin Kanamycin A	Antibiotic Bacterial	Infection Inflammation/Immunology
Kanamycin (Kanamycin A) is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .

HY-16566A

Kanamycin sulfate 5+ Cited Publications Kanamycin A sulfate	Bacterial Antibiotic	Infection
Kanamycin (Kanamycin A) sulfate is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin sulfate shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .

HY-17460A

Garenoxacin Mesylate hydrate BMS284756 Mesylate hydrate	Bacterial Topoisomerase DNA/RNA Synthesis Antibiotic	Infection
Garenoxacin (BMS284756) Mesylate hydrate is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms .

HY-17460

Garenoxacin BMS284756	Bacterial Topoisomerase DNA/RNA Synthesis Antibiotic	Infection
Garenoxacin (BMS284756) is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms .

HY-136943

K-41	Antibiotic Parasite Bacterial	Infection
K-41 is an orally active antibiotic. K-41 can be obtained from Streptomyces hygroscopicus. K-41 has antibacterial and antiplasmodial activity .

HY-100442S

Paquinimod-d5 ABR-215757-d₅; ABR 25757-d₅	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of *S100A8/S100A9. Paquinimod rescues the pneumonia* with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S1

Paquinimod-d5-1 ABR-215757-d₅-1; ABR 25757-d₅-1	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of *S100A8/S100A9. Paquinimod rescues the pneumonia* with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-N0802

Tenuigenin 1 Publications Verification Senegenin	NF-κB Bacterial	Infection Inflammation/Immunology
Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting NF-κB activation. Tenuigenin has anti-inflammatory effect .

HY-16908A

Lefamulin acetate 1 Publications Verification BC-3781 acetate
Lefamulin (BC-3781) acetate is an orally active antibiotic. Lefamulin acetate inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. Lefamulin acetate has anti-inflammatory activity. Lefamulin acetate can be used in the research of bacterial infections, such as bacterial pneumonia .

HY-16908

Lefamulin BC-3781
Lefamulin (BC-3781) is an orally active antibiotic. Lefamulin inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. Lefamulin has anti-inflammatory activity. Lefamulin can be used in the research of bacterial infections, such as bacterial pneumonia .

HY-17593

Solithromycin 2 Publications Verification CEM-101; OP-1068	Bacterial Antibiotic	Infection
Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with *IC₅₀s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae*, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis .

HY-19892

Brilacidin PMX 30063
Brilacidin (PMX 30063) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin is a defensin mimetic antibiotic compound .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .

HY-19892A

Brilacidin tetrahydrochloride PMX 30063 tetrahydrochloride	Bacterial Antibiotic	Infection
Brilacidin tetrahydrochloride (PMX 30063 tetrahydrochloride) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin tetrahydrochloride is a defensin mimetic antibiotic compound .

HY-131044

5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione	Bacterial Fungal	Infection
5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione (Compound 4) has antimicrobial, anti-diabetic and antioxidant activities. 5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione inhibits B. subtilis, S. aureus, K. pneumonia, E. coli, and S. typhi with MICs of 4.5-9.9 μΜ/mL, and inhibits A. niger and C. albicans with MICs of 4.99 μΜ/mL .

HY-14956

Nemonoxacin TG-873870	Antibiotic Bacterial	Infection Inflammation/Immunology
Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .

HY-106410A

Zabofloxacin hydrochloride DW-224a	Bacterial Topoisomerase Antibiotic	Infection
Zabofloxacin hydrochloride (DW-224a) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin hydrochloride has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia. Zabofloxacin hydrochloride is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP) .

HY-13832

Atovaquone 1 Publications Verification Atavaquone	Parasite Cytochrome P450 Antibiotic Bacterial	Infection Cancer
Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the *parasite’s mitochondrial cytochrome bc1* complex*. Atovaquone is against human and P. falciparum* cytochrome bc1 activity with IC₅₀ values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia .

HY-106410

Zabofloxacin DW-224a Free base	Bacterial Topoisomerase Antibiotic	Infection
Zabofloxacin (DW-224a Free base) is a potent and seletive inhibitor of the bacterial type II and IV topoisomerases. Zabofloxacin has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia. Zabofloxacin is a novel fluoronaphthyridone quinolone that is considered as an alternative antibiotic for treatment of quinolone-susceptible (QSSP) and quinolone-resistant gonorrhea (QRSP) .

HY-N1654

2',3'-Dehydrosalannol	Bacterial	Infection
2',3'-Dehydrosalannol is a potent antibacterial agent. 2',3'-Dehydrosalannol shows antibacterial activity against K. pneumonia ATCC 13883, P. aeruginosa ATCC 27853, S. aureus ATCC 25922, E. coli ATCC 11775, and E. faecalis ATCC 10541, with MIC values of 0.78, 1.56, 1.56, 6.25, and 25 µg/mL, respectively .

HY-N2187

Deoxyshikonin 1 Publications Verification
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .

HY-13832S2

Atovaquone-d5 Atavaquone-d₅	Isotope-Labeled Compounds Parasite Cytochrome P450 Antibiotic	Infection
Atovaquone-d₅ is the deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

HY-13832S3

cis-Atovaquone-d4 cis-Atavaquone-d₄	Isotope-Labeled Compounds Parasite Cytochrome P450 Antibiotic	Infection
cis-Atovaquone-d₄ is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

HY-P99583

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

HY-14865C

Omadacycline hydrochloride Maximum Cited Publications 19 Publications Verification PTK0796 hydrochloride; Amadacycline hydrochloride	Bacterial Antibiotic	Infection
Omadacycline (PTK 0796) hydrochloride, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline hydrochloride acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline hydrochloride possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline hydrochloride can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .

HY-14865

Omadacycline Maximum Cited Publications 19 Publications Verification PTK 0796; Amadacycline	Bacterial Antibiotic	Infection
Omadacycline (PTK 0796), a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .

HY-14865A

Omadacycline mesylate PTK 0796 mesylate; Amadacycline mesylate	Bacterial Antibiotic	Infection
Omadacycline (PTK 0796) mesylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline mesylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline mesylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline mesylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .

HY-14865B

Omadacycline tosylate Maximum Cited Publications 19 Publications Verification PTK 0796 tosylate; Amadacycline tosylate	Bacterial Antibiotic	Infection
Omadacycline (PTK 0796) tosylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline tosylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline tosylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline tosylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections .

HY-135748A

Poly (I:C):Kanamycin (1:1) (sodium) 10+ Cited Publications	Toll-like Receptor (TLR) Apoptosis	Infection Cancer
Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .

CSP1	Bacterial	Infection
CSP1 is a potent and selective ComD1 receptor agonist, with an IC₅₀ of 10.3 nM. CSP1 is a major variants of competence-stimulating peptide (CSP), and it can regulate genetic transformation of S. pneumonia by modulating quorum sensing (QS). CSP1 can act as an antibacterial agent .

Amphomycin	Bacterial Antibiotic	Infection
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .

Tosatoxumab KBSA301; AR-301	Antibiotic	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16566A

Kanamycin sulfate 5+ Cited Publications Kanamycin A sulfate	Structural Classification Anti-inflammation/Immunoregulatory Classification of Application Fields Source classification Antibacterial Disease Research Other Antibiotics Infection Plant Cell Culture Microorganisms Antibiotics Resistance Selection Mammalian Cell Culture Disease Research Fields	Bacterial Antibiotic
Kanamycin (Kanamycin A) sulfate is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin sulfate shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .

HY-N0802

Tenuigenin 1 Publications Verification Senegenin	Triterpenes Classification of Application Fields Terpenoids Source classification Polygalaceae Plants Disease Research Fields Inflammation/Immunology Polygala tenuifolia Willd.	NF-κB Bacterial
Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting NF-κB activation. Tenuigenin has anti-inflammatory effect .

HY-107222

Lysionotin	Gesneriaceae Structural Classification Lysinonotus pauciflorus Maxim. Flavonoids Classification of Application Fields Flavones Source classification Plants Inflammation/Immunology Disease Research Fields	Others
Lysionotin is a flavonoid isolated from Gesneriaceae family. Lysionotin efficiently inhibit α-Toxin (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo. Lysionotin has the potential for the treatment of S. aureus induced pneumonia .

HY-136943

K-41	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Antibiotic Parasite Bacterial
K-41 is an orally active antibiotic. K-41 can be obtained from Streptomyces hygroscopicus. K-41 has antibacterial and antiplasmodial activity .

HY-N1654

2',3'-Dehydrosalannol	Infection Natural Products Classification of Application Fields Source classification Plants Azadirachta indica A. Juss. Disease Research Fields Meliaceae	Bacterial
2',3'-Dehydrosalannol is a potent antibacterial agent. 2',3'-Dehydrosalannol shows antibacterial activity against K. pneumonia ATCC 13883, P. aeruginosa ATCC 27853, S. aureus ATCC 25922, E. coli ATCC 11775, and E. faecalis ATCC 10541, with MIC values of 0.78, 1.56, 1.56, 6.25, and 25 µg/mL, respectively .

Cat. No.	Product Name	Chemical Structure

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of *S100A8/S100A9. Paquinimod rescues the pneumonia* with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of *S100A8/S100A9. Paquinimod rescues the pneumonia* with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-13832S2

Atovaquone-d5

Atovaquone-d₅ is the deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

HY-13832S3

cis-Atovaquone-d4

cis-Atovaquone-d₄ is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks